How should tenofovir disoproxil fumarate (TDF)–induced elevation in serum creatinine be evaluated and managed?

Management of Tenofovir Disoproxil Fumarate-Induced Creatinine Elevation

If creatinine elevation occurs on TDF, switch to tenofovir alafenamide (TAF), entecavir, or besifovir immediately—do not continue TDF with dose adjustment alone. 1, 2

Initial Assessment When Creatinine Rises

When you detect an elevation in serum creatinine in a patient on TDF, immediately assess for:

• Magnitude of decline: Calculate if eGFR has dropped >25% from baseline AND fallen to <60 mL/min/1.73 m² 3
• Evidence of proximal tubular dysfunction: Check for euglycemic glycosuria, hypophosphatemia (serum phosphorus <2.5 mg/dL), increased urinary phosphorus excretion, or new/worsening proteinuria 1, 3
• Concurrent nephrotoxins: Review for NSAIDs (especially high-dose or multiple), boosted protease inhibitors (particularly atazanavir or ritonavir), or other nephrotoxic medications 3, 4

The FDA label explicitly warns that TDF should be discontinued if renal function worsens, particularly with evidence of proximal tubular dysfunction 4.

When to Switch Therapy

Switch TDF immediately if any of the following occur:

• eGFR decline >25% from baseline with current eGFR <60 mL/min/1.73 m² 3, 5
• New or worsening proteinuria/albuminuria 3
• Hypophosphatemia (<2.5 mg/dL) with or without other Fanconi syndrome features 1
• Euglycemic glycosuria 3

Do not simply dose-adjust TDF and continue—the guidelines are clear that switching to an alternative agent is the appropriate management 1, 2.

Preferred Alternative Agents

For Hepatitis B Treatment:

First-line alternatives (in order of preference based on 2022 KASL guidelines) 1:

1. Tenofovir alafenamide (TAF): Preferred option showing significant renal function improvement after switch

   • Studies demonstrate eGFR improvement of +4.2 mL/min at 144 weeks post-switch vs. -0.9 mL/min in those continuing TDF 1
   • Median eGFR change +0.94 mL/min vs. -2.74 mL/min in continuers at 48 weeks 1

2. Entecavir: Appropriate alternative, particularly in treatment-naïve patients

   • No renal dose adjustment needed until CrCl <50 mL/min 1

3. Besifovir: Shows renal recovery after switch

   • eGFR recovered to baseline after switching from TDF at 144 weeks 1

For HIV Treatment:

Switch to TAF-based regimen or entecavir (if treating HBV co-infection) 2, 5. Abacavir is an alternative if TAF unavailable, though requires HLA-B*5701 screening 3.

Expected Recovery Timeline

After switching from TDF:

• Renal function: Improvement typically begins within weeks, with continued recovery over 48-144 weeks 1
• Bone mineral density: Recovery to baseline by week 240 after switch 1
• Phosphate levels: Significant recovery observed, particularly in those switched to entecavir (β = +0.111 mg/dL/year post-switch) 6

Monitoring After Switch

Continue monitoring:

• Serum creatinine and eGFR: Monthly for first 3-6 months, then every 3 months 1, 2
• Serum phosphorus: Every 3 months if previously low 1
• Urine protein/albumin: Every 3-6 months 2

Critical Pitfalls to Avoid

1. Do not continue TDF with dose adjustment alone when renal dysfunction develops—this is inadequate management 1, 2, 3

2. Do not wait for severe renal impairment (eGFR <30 mL/min) before switching—intervene at eGFR <60 mL/min with >25% decline 3

3. Do not overlook proximal tubular dysfunction markers (hypophosphatemia, glycosuria)—these indicate TDF toxicity even with preserved eGFR 3

4. Do not forget to check for concurrent nephrotoxins—particularly boosted protease inhibitors and NSAIDs, which significantly increase TDF nephrotoxicity risk 3, 4

5. For HBV patients, ensure the alternative maintains viral suppression—TAF and entecavir are both highly effective 1

The evidence strongly supports that TDF-induced renal dysfunction is largely reversible with prompt switching to safer alternatives, making early recognition and intervention critical for preventing permanent kidney damage.